IMPORTANT WARNING:
Daclizumab may cause serious or life-threatening liver damage. The risk of liver damage may be increased in people taking other medications known to cause liver damage, and in people who already have liver disease. Tell your doctor if you have or ever had liver problems or hepatitis. Your doctor may tell you not to use daclizumab injection. Tell your doctor and pharmacist about all the medications you are taking so they can check whether any of your medications may increase the risk that you will develop liver damage during your treatment with daclizumab. Your doctor will monitor you for signs of liver problems during and for 6 months after your treatment with daclizumab. If you experience any of the following symptoms, call your doctor immediately: nausea, vomiting, extreme tiredness, unusual bleeding or bruising, lack of energy, loss of appetite, pain in the upper right part of the stomach, yellowing of the skin or eyes, dark-colored urine, or flu-like symptoms.
Daclizumab may cause serious immune system disorders (conditions that occur when the immune system attacks healthy cells in the body). Tell your doctor if you have or have ever had skin problems, including eczema or psoriasis. If you experience any of the following symptoms, call your doctor immediately: redness, itching, or scaling of the skin; swollen glands in the neck, armpits, or groin; diarrhea; bloody stools; stomach pain; or any new, unexplained symptom affecting any part of your body.
Because of the risks with this medication, daclizumab injection is available only through a special restricted distribution program. A program has been set up by the manufacturer of daclizumab to be sure that people do not use daclizumab injection without the necessary monitoring called the Zinbryta Risk Evaluation and Mitigation Strategies (REMS) Program. Your doctor and your pharmacist must be registered with the Zinbryta REMS program. Ask your doctor for more information about this program and how you will receive your medication.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests before, during, and for 6 months after your final dose to check your body's response to daclizumab injection.
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with daclizumab injection and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) to obtain the Medication Guide.
Talk to your doctor about the risk(s) of receiving daclizumab injection.
IMPORTANT NOTICE:
Daclizumab injection is no longer available. If you are currently using daclizumab, you should call your doctor to discuss switching to another treatment.